SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)
MUNICH & COPENHAGEN, February 4, 2020— SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and InProTher Aps (“InProTher”), a Danish start up supported by Novo Nordisk Foundation’s BioInnovation Institute (BII), today announced a broad licensing…
Inprother will be presenting at Biotech Showcase 2020
Please meet us at the 2020 Biotech Showcase in San Francisco, where Inprother CBO, Dr. Mathias Kroll will be presenting Inprother. The presentation will take place at 10.00AM January 4th 2020 at: Hilton San Francisco Union Square 333 O’Farrell Street – Ballroom Level San Francisco, CA 94102
InProTher pitch at Novo BII demo-day by Peter J. Holst
InProTher treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where InProTher is presented by Associate Professor Peter Johannes Holst.
InProTher presentation by Peter J. Holst
InProTher treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where InProTher is presented by Associate Professor Peter Johannes Holst.
Inprother got investment by Novo Nordisk Foundation
InProTher is one of the three companies to join the BII Creation House program run by Novo Nordisk Foundation. After a successful Business Acceleration Academy, InProTher was recommended for the program by an external committee and approved by the BII Board of Directors. In the…